350 related articles for article (PubMed ID: 30576085)
21. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Ogawa E; Furusyo N; Nguyen MH
Drug Des Devel Ther; 2017; 11():3197-3204. PubMed ID: 29158666
[TBL] [Abstract][Full Text] [Related]
23. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.
Ogawa E; Jun DW; Toyoda H; Hsu YC; Yoon EL; Ahn SB; Yeh ML; Do S; Trinh HN; Takahashi H; Enomoto M; Kawada N; Yasuda S; Tseng CH; Kawashima K; Lee HA; Inoue K; Haga H; Do AT; Maeda M; Hoang JH; Cheung R; Ueno Y; Eguchi Y; Furusyo N; Yu ML; Tanaka Y; Nguyen MH
Aliment Pharmacol Ther; 2024 Jan; 59(2):239-248. PubMed ID: 37882252
[TBL] [Abstract][Full Text] [Related]
24. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.
Huang YS; Cheng CY; Sun HY; Cheng SH; Lu PL; Lee CH; Lee YT; Tsai HC; Yang CJ; Liu CE; Liou BH; Lin SP; Huang SH; Ho MW; Tang HJ; Hung CC;
Microbiol Spectr; 2023 Jun; 11(3):e0512522. PubMed ID: 36988457
[TBL] [Abstract][Full Text] [Related]
25. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38690711
[TBL] [Abstract][Full Text] [Related]
26. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Buti M; Tsai N; Petersen J; Flisiak R; Gurel S; Krastev Z; Aguilar Schall R; Flaherty JF; Martins EB; Charuworn P; Kitrinos KM; Subramanian GM; Gane E; Marcellin P
Dig Dis Sci; 2015 May; 60(5):1457-64. PubMed ID: 25532501
[TBL] [Abstract][Full Text] [Related]
27. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
28. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Gupta SK; Post FA; Arribas JR; Eron JJ; Wohl DA; Clarke AE; Sax PE; Stellbrink HJ; Esser S; Pozniak AL; Podzamczer D; Waters L; Orkin C; Rockstroh JK; Mudrikova T; Negredo E; Elion RA; Guo S; Zhong L; Carter C; Martin H; Brainard D; SenGupta D; Das M
AIDS; 2019 Jul; 33(9):1455-1465. PubMed ID: 30932951
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
Liang LY; Yip TC; Lai JC; Lam AS; Tse YK; Hui VW; Chan HL; Wong VW; Wong GL
J Med Virol; 2022 Sep; 94(9):4440-4448. PubMed ID: 35581529
[TBL] [Abstract][Full Text] [Related]
30. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
[TBL] [Abstract][Full Text] [Related]
31. Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.
Seto WK; Asahina Y; Brown TT; Peng CY; Stanciu C; Abdurakhmanov D; Tabak F; Nguyen TT; Chuang WL; Inokuma T; Ikeda F; Santantonio TA; Habersetzer F; Ramji A; Lau AH; Suri V; Flaherty JF; Wang H; Gaggar A; Subramanian GM; Mukewar S; Brunetto MR; Fung S; Chan HL
Clin Gastroenterol Hepatol; 2018 Jun; ():. PubMed ID: 29933096
[TBL] [Abstract][Full Text] [Related]
32. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
[TBL] [Abstract][Full Text] [Related]
33. Real-world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B.
Hige S; Aoki K; Nakamoto D; Flaherty JF; Botros I; Mizutani H; Ishizaki A; Konishi H; Yuan J; Jinushi M; Ng LJ
J Viral Hepat; 2024 Apr; 31(4):165-175. PubMed ID: 38163911
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
Lee HJ; Kim SJ; Kweon YO; Park SY; Heo J; Woo HY; Hwang JS; Chung WJ; Lee CH; Kim BS; Suh JI; Tak WY; Jang BK
PLoS One; 2018; 13(1):e0190581. PubMed ID: 29329305
[TBL] [Abstract][Full Text] [Related]
35. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice.
Song JE; Lee CH; Kim BS
Korean J Intern Med; 2019 Jul; 34(4):802-810. PubMed ID: 30959583
[TBL] [Abstract][Full Text] [Related]
37. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
[TBL] [Abstract][Full Text] [Related]
38. Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection.
Childs-Kean LM; Egelund EF; Jourjy J
Pharmacotherapy; 2018 Oct; 38(10):1051-1057. PubMed ID: 30120841
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
